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The Malignant Conversion Step of Mouse
Skin Carcinogenesis
by Stuart H. Yuspa,* Henry Hennings,* Dennis Roop,*
James Strickland,* and David A. Greenhalgh*
Multiple benign squamous papillomas commonly precede the development of an occasional squamous
cell carcinoma in mouse skin carcinogenesis. The incidence of carcinomas can be enhanced by treating
papilloma-bearing mice with mutagens such as urethane, nitroquinoline-N-oxide, or cisplatinum. This
observation suggests that agenetic change is required formalignant conversion. The malignant phenotype
is characterized by a marked reduction in the transcription ofspecific epidermal differentiation markers,
a pattern which is useful for the early diagnosis of malignant conversion. Cells expressing a benign
phenotype can be obtained by introducing the v-rasHa oncogene into cultured epidermal cells by a repli-
cation-defective retrovirus. Alternatively, benign tumor cells can be cultured from papillomas induced by
chemical carcinogens in vivo or from carcinogen-treated mouse epidermis. In all cases, the benign phen-
otype in vitro is characterized by an altered biological response to changes in extracellular calcium, an
importantdeterminantofthedifferentiation stateofculturednormalkeratinocytes. Transfection ofcloned
plasmid DNA into benign tumor cells has revealed that transforming constructs ofthe fos oncogene induce
malignant conversion, whereas myc and adenovirus EIA oncogenes do not. The fos carcinomas do not
express differentiation-specific epidermal markers and secrete proteases such as transin and urokinase, a
set ofcharacteristics previously noted forchemically induced skin carcinomas. Cultured normal epidermal
cells, exposed to the v-ras and the v-fos oncogenes simultaneously, are malignantly transformed. Alone,
the fos oncogene does not detectably alter the phenotype of normal keratinocytes. These studies indicate
that a limited number of genes is involved in epidermal carcinogenesis.
Introduction
In chemically induced mouse skin carcinogenesis, ep-
idermal cancers are commonly preceded by the appear-
ance of multiple benign squamous papillomas. Opera-
tionally, at least three distinct steps have been defined
in mouse skin carcinogenesis (1). The first stage, initi-
ation, occurs rapidly, is irreversible, and is commonly
caused by mutagens. A single amino acid substitution
mutation in the codon 61 of the c-rasHa gene has been
causally related to the initiation step (2,3). Further-
more, introduction of the v-rasHa gene into normal ep-
idermal cells is sufficient to initiate benign tumor for-
mation (4,5). Initiated epidermal cells are resistant to
signals that induce terminal differentiation in normal
cells (6,7).
The second stage of mouse skin carcinogenesis, pro-
motion, results from repeated and frequent applications
of promoting substances that are generally nonmuta-
gens (1). Mosttumorpromotersworkbychangingtissue
homeostasis, providing an environment conducive for
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the selective clonal outgrowth of initiated cells (8,9).
Initiation and promotion results in the production of
multiple benign squamous papillomas, each of which is
a monoclonal expansion of a single initiated cell (10).
The majority ofpapillomas remainbenignthroughout
the lifetime of the animal (11). The low rate of spon-
taneous malignant conversion can be accelerated and
the frequency enhanced by exposure ofpapilloma-bear-
ing animals to mutagenic initiating agents (12-14). The
introduction of specific oncogenes into benign tumor
cells can also cause malignant conversion (15-17). To-
gether these results suggest that a second somatic mu-
tation in a benign tumor cell is sufficient to cause ma-
lignant conversion.
Genetic Basis of Malignant
Conversion
Cell lines that produce papillomas when grafted as
part of a reconstituted skin have been established in
culture from chemically induced tumors (18). Two of
these lines, SP-1 and 308, were derived from Sencar
and Balb/c mice, respectively, and contain an activated
c-rasHa genecontaining an A-> T transversion in codon
61 (2,18). These cell lines were stably transfected with
plasmid DNA containing either a rearranged murine194 YUSPA ET AL.
plasmacytoma-derived c-myc (minus exon 1), adenovi-
rus 5 ElA, FBJ v-fos, or a human c-fos/FBJ v-fos chi-
mera using cotransfection with a neomycin-resistance
gene contained in pSV2neo to select for transformants
(16). TheElA andmyc-containingplasmidsdidnotalter
the benign phenotype. Bothfos constructs caused ma-
lignant conversion in either cell line as defined by the
squamous cell carcinoma histology of tumors from
grafted cells and the development of carcinomas after
SC injection into athymic nude mice. The carcinomas
produced by thefos oncogenes were devoid ofstaining
for mouse keratin 1 (K1) but were positive for keratin
14 (K14), amarkerpatternpreviouslyseeninchemically
induced carcinomas (19). Tumors from ElA, myc, or
pSV2neo transfectants express Ki, although in a focal
distribution, a pattern common to dysplastic papillomas
(19). fos-Induced carcinomas were indistinguishable
from parental benign tumor cells by several in vitro
markers oftransformation. Thefos transfection did not
alter expression of the mutant c-rasHa to cause malig-
nant conversion.
Undocumented genetic changes from establishment
of parental cells in vitro could have contributed to the
complementary action ofthefos oncogene in malignant
conversion in the foregoing studies. Cooperativity
amongras andfosoncogenesincarcinomainductionwas
therefore tested directly in primary epidermal cells.
Three days afterisolation and cultivation, newbornker-
atinocytes were co-infected with v-rasHa and v-fos re-
troviruses that were replication defective (5,20). In-
fected keratinocytes were removed from culture and
tested fortumorformationinvivo. Ineightindependent
experiments, combined exposure to v-fos and v-rasHa
resulted in squamous cell carcinomas, while exposure
to v-rasHa only produced squamous papillomas and v-
fos only produced normal skin. The tumors evolving
from combined infection with v-fos and v-rasHa ex-
pressed K14butnotKi. Nucleicacidhybridization stud-
ies of RNA isolated from tumors from all groups indi-
cated that the v-rasHa oncogene was expressed in the
papillomas and both the v-rasHa and v-fos oncogenes
were expressed in carcinomas. These results support
the conclusion that cooperation between afos and ras
oncogene is sufficient to produce squamous carcinomas
of keratinocyte origin. Furthermore, activation offos
alone may yield anormal skinphenotype, although such
cells could experience malignant conversion by activa-
tion of a single complementing rasHa oncogene.
Conclusions
Our studies indicate that a single gene is sufficient to
convert benign skin tumors to malignancy. Under cer-
tain conditions thefos oncogene can cause this change.
the fos oncogene may exert its converting action via
transcriptional enhancement of specific cellular genes,
in conjunction with API, a mammalian transcriptional
activator (21,22). Among the genes regulated by fosl
AP1 are secreted proteases, such as transin and colla-
genase (23). The elaboration of proteases as an early
event in malignant conversion is consistent with the
phenotypic differences cataloged amongbenign and ma-
lignant squamous tumors (19,24). As initiated cells al-
ready express an intrinsic defect in their differentiation
program by virtue of the initiating mutation, protease
secretion could lead to a major disruption ofthe extra-
cellular environment (e.g., stroma, basement mem-
brane) required to maintain proper structural organi-
zation in the benign tumor and thus proper expression
ofdifferentiation markers. Loss ofextrinsic components
oftissue regulation could cause the dysplastic histotype
observed duringmalignant progression. Dysplasia is as-
sociated with loss ofspecific markers when analyzed by
molecular probes (25). The loss ofextrinsic control ofa
normal regulatory program could also deregulate the
positional control ofproliferation and lead to additional
genetic changes associated with malignant progression.
A number of inhibitors have been described for in-
dividual proteases within a protease cascade (26). Cys-
tatin A, a specific inhibitor of thiol proteases, is com-
monlydeficientinmalignant, butnotbenign skintumors
(27). The loss ofan inhibitor could result in an enhance-
ment of proteolytic activity, having similar phenotypic
consequences as enhanced expression of the protease.
One implication of such reasoning is that protease in-
hibitors could comprise one class of tumor suppressor
genes.
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